NCNA - ニュ―カナ (NuCana plc) ニュ―カナ

 NCNAのチャート


 NCNAの企業情報

symbol NCNA
会社名 NuCana Plc (ニュ―カナ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin a novel nucleoside analog.  ニュ―カナはイギリスのバイオ医薬品企業。臨床段階で、がん治療の医薬品ポ―トフォリオの開発に従事する。主に卵巣がん、胆道がん、膵臓がん、結腸直腸がん、乳がん、血液のがんに対する治療薬を開発、英国と米国で事業を展開する。同社独自のプラットフォ―ム技術を利用し、抗がん剤を製造する。本社所在地はエディンバラ。   NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
本社所在地 3 Lochside Way Edinburgh EH12 9DT GBR
代表者氏名 Christopher B. Wood クリストファーB.ウッド
代表者役職名 Chairman of the Board Co-Founder_Chief Medical Officer
電話番号 +44 131-248-3660
設立年月日 35462
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 20人
url www.nucana.com
nasdaq_url https://www.nasdaq.com/symbol/ncna
adr_tso 8945249
EBITDA EBITDA(百万ドル) -38.10040
終値(lastsale) 20.89
時価総額(marketcap) 186866251.61
時価総額 時価総額(百万ドル) 645.76620
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) ー
当期純利益 当期純利益(百万ドル) -34.52053
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 NuCana PLC (ADR) revenues was not reported. Net loss increased 76% to £7.7M. Higher net loss reflects Research and development expenses increase from £3.7M to £8.9M (expense) Administrative expenses increase from £637K to £2.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -£0.14 to -£0.24.

 NCNAのテクニカル分析


 NCNAのニュース

   NuCana Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/19 16:01:00 Benzinga
EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the second quarter ended June 30, 2020 …
   Why NuCana (NCNA) Stock Might be a Great Pick  2020/06/02 12:59:00 Zacks Investment Research
NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?  2020/02/25 08:46:00 Zacks Investment Research
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.
   NuCana plc (NCNA) Shares March Higher, Can It Continue?  2019/09/06 14:06:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).
   NuCana Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/19 16:01:00 Benzinga
EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the second quarter ended June 30, 2020 …
   Why NuCana (NCNA) Stock Might be a Great Pick  2020/06/02 12:59:00 Zacks Investment Research
NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?  2020/02/25 08:46:00 Zacks Investment Research
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.
   NuCana plc (NCNA) Shares March Higher, Can It Continue?  2019/09/06 14:06:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).
   Why NuCana (NCNA) Stock Might be a Great Pick  2020/06/02 12:59:00 Zacks Investment Research
NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?  2020/02/25 08:46:00 Zacks Investment Research
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.
   NuCana plc (NCNA) Shares March Higher, Can It Continue?  2019/09/06 14:06:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).
   NuCana Stops Patient Enrollment in Pancreatic Cancer Study  2019/08/21 15:08:00 Zacks Investment Research
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ニュ―カナ NCNA NuCana plc)

 twitter  (公式ツイッターやCEOツイッターなど)